![Frontiers | Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective Frontiers | Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective](https://www.frontiersin.org/files/Articles/649203/fbioe-09-649203-HTML/image_m/fbioe-09-649203-g001.jpg)
Frontiers | Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective
![Cells | Free Full-Text | Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing Cells | Free Full-Text | Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing](https://www.mdpi.com/cells/cells-09-01608/article_deploy/html/images/cells-09-01608-g001.png)
Cells | Free Full-Text | Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
![Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects | Signal Transduction and Targeted Therapy Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-019-0089-y/MediaObjects/41392_2019_89_Fig1_HTML.png)
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects | Signal Transduction and Targeted Therapy
![CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia | Arteriosclerosis, Thrombosis, and Vascular Biology CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/f1129e2e-a147-4544-97f7-ac57350b8f59/12fig01.gif)
CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia | Arteriosclerosis, Thrombosis, and Vascular Biology
![Improved loss-of-function CRISPR-Cas9 genome editing in human cells concomitant with inhibition of TGF-β signaling: Molecular Therapy - Nucleic Acids Improved loss-of-function CRISPR-Cas9 genome editing in human cells concomitant with inhibition of TGF-β signaling: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/395770d9-56cc-40f6-a839-b0795045b005/fx1_lrg.jpg)